The SRH cell line is derived from a mesenchymal tumor that is reflected by cell surface expression of mesenchymal markers, including CD10, CD44, CD73, CD90, CD105, CD146, and CD166 concomitant with the lack of the hematopoietic lineage surface markers CD14, CD19, and CD45 [60,61,62,63]. Here, CD19 is linked to neoplasm.